|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/15/22 AIM ImmunoTech Inc. 10-Q 6/30/22 72:6M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.44M
2: EX-10.86 Material Contract HTML 25K
3: EX-10.87 Material Contract HTML 25K
4: EX-10.88 Material Contract HTML 22K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 26K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 25K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 21K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 20K
14: R1 Cover HTML 72K
15: R2 Consolidated Balance Sheets (Unaudited) HTML 103K
16: R3 Consolidated Balance Sheets (Unaudited) HTML 35K
(Parenthetical)
17: R4 Consolidated Statements of Comprehensive Loss HTML 93K
(Unaudited)
18: R5 Consolidated Statements of Changes in HTML 58K
Stockholders' Equity (Unaudited)
19: R6 Consolidated Statements of Cash Flows (Unaudited) HTML 116K
20: R7 Business and Basis of Presentation HTML 34K
21: R8 Net Loss Per Share HTML 24K
22: R9 Equity-Based Compensation HTML 148K
23: R10 Marketable Securities HTML 49K
24: R11 Accrued Expenses HTML 34K
25: R12 Property and Equipment, net HTML 37K
26: R13 Patents HTML 41K
27: R14 Stockholders? Equity HTML 65K
28: R15 Cash and Cash Equivalents HTML 23K
29: R16 Recent Accounting Pronouncements HTML 22K
30: R17 Fair Value HTML 164K
31: R18 Financing Obligation Arising from Sale Leaseback HTML 28K
Transaction
32: R19 Leases HTML 55K
33: R20 Research, Consulting and Supply Agreements HTML 31K
34: R21 Subsequent Events HTML 25K
35: R22 Equity-Based Compensation (Tables) HTML 147K
36: R23 Marketable Securities (Tables) HTML 48K
37: R24 Accrued Expenses (Tables) HTML 32K
38: R25 Property and Equipment, net (Tables) HTML 33K
39: R26 Patents (Tables) HTML 41K
40: R27 Fair Value (Tables) HTML 146K
41: R28 Leases (Tables) HTML 31K
42: R29 Business and Basis of Presentation (Details HTML 21K
Narrative)
43: R30 Net Loss Per Share (Details Narrative) HTML 24K
44: R31 Schedule of Stock Option Activity (Details) HTML 80K
45: R32 Schedule of Unvested Stock Option Activity HTML 61K
(Details)
46: R33 Equity-Based Compensation (Details Narrative) HTML 26K
47: R34 Schedule of Available for Sale (Details) HTML 25K
48: R35 Schedule of Equity Securities (Details) HTML 26K
49: R36 Marketable Securities (Details Narrative) HTML 25K
50: R37 Schedule of Accrued Expenses (Details) HTML 30K
51: R38 Schedule of Property and Equipment (Details) HTML 32K
52: R39 Property and Equipment, net (Details Narrative) HTML 24K
53: R40 Schedule of Patents, Trademark Rights (Details) HTML 27K
54: R41 Schedule of Amortization of Patents and Trademarks HTML 35K
(Details)
55: R42 Patents (Details Narrative) HTML 23K
56: R43 Stockholders? Equity (Details Narrative) HTML 157K
57: R44 Schedule of Assumptions to Estimate Fair Value of HTML 63K
Warrants (Details)
58: R45 Schedule of Range of Probabilities (Details) HTML 26K
59: R46 Schedule of Assets and Liabilities Measured at HTML 34K
Fair Value on a Recurring Basis (Details)
60: R47 Schedule of Changes in Level 3 Liabilities HTML 26K
Measured at Fair Value on a Recurring Basis
(Details)
61: R48 Schedule of Assets and Liabilities Measured at HTML 33K
Fair Value on a NonRecurring Basis (Details)
62: R49 Schedule of Assets and Liabilities Measured at HTML 28K
Fair Value on a NonRecurring Basis (Details)
(Parenthetical)
63: R50 Fair Value (Details Narrative) HTML 31K
64: R51 Financing Obligation Arising from Sale Leaseback HTML 39K
Transaction (Details Narrative)
65: R52 Schedule of Operating lease Future Payments HTML 34K
(Details)
66: R53 Leases (Details Narrative) HTML 67K
67: R54 Research, Consulting and Supply Agreements HTML 41K
(Details Narrative)
70: XML IDEA XML File -- Filing Summary XML 121K
68: XML XBRL Instance -- form10-q_htm XML 1.39M
69: EXCEL IDEA Workbook of Financial Reports XLSX 106K
10: EX-101.CAL XBRL Calculations -- aim-20220630_cal XML 155K
11: EX-101.DEF XBRL Definitions -- aim-20220630_def XML 475K
12: EX-101.LAB XBRL Labels -- aim-20220630_lab XML 887K
13: EX-101.PRE XBRL Presentations -- aim-20220630_pre XML 682K
9: EX-101.SCH XBRL Schema -- aim-20220630 XSD 130K
71: JSON XBRL Instance as JSON Data -- MetaLinks 309± 441K
72: ZIP XBRL Zipped Folder -- 0001493152-22-022600-xbrl Zip 266K
Exhibit 10.87
SECOND AMENDMENT TO AGREEMENT OF SALE AND PURCHASE
THIS SECOND AMENDMENT TO AGREEMENT OF SALE AND PURCHASE (this “Second Amendment”) is made as of August 2, 2022, by and between AIM IMMUNOTECH INC., a Delaware corporation (“Seller”), and ACELLORIES, INC., a New York corporation (“Buyer”).
WHEREAS, Seller and Buyer have executed that certain Agreement of Sale and Purchase dated March 3, 2022, as amended by a First Amendment to Agreement of Sale and Purchase dated June 27, 2022 (collectively, the “Purchase Agreement”) for the purchase of certain Property, as defined in the Purchase Agreement, situate in the City of Brunswick, Middlesex County, New Jersey and commonly known as 783 Jersey Avenue; and
WHEREAS, Seller and Buyer now desire to make certain amendments to the Purchase Agreement, upon and subject to the terms and conditions of this Second Amendment.
NOW THEREFORE, the parties hereto, in consideration of the mutual promises hereinafter set forth, and intending to be legally bound, hereby agree as follows:
1. The Closing Date is hereby extended to August 31, 2022, subject to Seller’s right to further extend the Closing date as set forth in Section 4(b) of the Purchase Agreement.
2. All capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Purchase Agreement. This Second Amendment may be signed in counterpart(s). For purposes of this Second Amendment, facsimile or electronic signatures shall constitute original signatures. The transmission of a signed counterpart of this Second Amendment by electronic signature, facsimile or by portable document file shall have the same force and effect as delivery of an original signed counterpart of this Second Amendment, and shall constitute valid and effective delivery for all purposes. Except as expressly modified hereby, and in all respects, the remainder of the Purchase Agreement is hereby ratified and shall continue in full force and effect without modification. Nothing in this Second Amendment shall be construed as, or otherwise effect, a waiver of any right, remedy, power or privilege of Seller or Buyer under the Purchase Agreement, all of which are expressly reserved.
[Signatures on Following Page]
C:
IN WITNESS WHEREOF, the parties hereto have caused this Second Amendment to be duly executed as of the day and year first above written.
| Seller: | ||
| AIM IMMUNOTECH INC. | ||
| By: | /s/Peter W. Rodino | |
| Name: | Peter W. Rodino | |
| Title: | C.O.O. | |
| Buyer: | ||
| ACELLORIES, INC. | ||
| By: | /s/Albert Lalou | |
| Name: | Albert Lalou | |
| Title: | V.P. | |
C:
| - C: 2- |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 8/31/22 | ||||
| Filed on: | 8/15/22 | |||
| 8/2/22 | ||||
| For Period end: | 6/30/22 | |||
| 6/27/22 | ||||
| 3/3/22 | 4, 8-K | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/19/24 AIM ImmunoTech Inc. S-1 6:628K M2 Compliance LLC/FA 4/01/24 AIM ImmunoTech Inc. 10-K 12/31/23 84:8.7M M2 Compliance LLC/FA 11/14/23 AIM ImmunoTech Inc. 10-Q 9/30/23 64:5.5M M2 Compliance LLC/FA 8/14/23 AIM ImmunoTech Inc. 10-Q 6/30/23 63:5.3M M2 Compliance LLC/FA 5/15/23 AIM ImmunoTech Inc. 10-Q 3/31/23 65:4.7M M2 Compliance LLC/FA 3/31/23 AIM ImmunoTech Inc. 10-K 12/31/22 87:8.7M M2 Compliance LLC/FA 11/14/22 AIM ImmunoTech Inc. 10-Q 9/30/22 75:5M M2 Compliance LLC/FA |